Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Shalini Sharp Biography and Net Worth

CFO of Ultragenyx Pharmaceutical

Shalini Sharp joined Ultragenyx in May 2012 as Chief Financial Officer and Senior Vice President, Finance. She is a member of the Senior Management Team and is responsible for leading the corporate finance function, including strategic financial planning, accounting, budgeting and forecasting, financial analysis, general risk analysis, andfinancing activities. Shalini Sharp is a member of the Board of Directors of Agenus Inc. (formerly Antigenics Inc.), a publicly traded biotechnology firm, where she served as Chief Financial Officer from 2006 to 2012. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development. Prior to Agenus, Shalini Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that company's restructing. With 16 years of industry experience, Shalini Sharp has spearheaded numerous financing and business development transactions that have been critical to the success of Agenus and Elan. Prior to Elan, Shalini Sharp was a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices.

What is Shalini Sharp's net worth?: The estimated net worth of Shalini Sharp is at least $4.46 million as of August 17th, 2020. Ms. Sharp owns 100,747 shares of Ultragenyx Pharmaceutical stock worth more than $4,457,047 as of April 26th. This net worth approximation does not reflect any other investments that Ms. Sharp may own. Learn More about Shalini Sharp's net worth.
How do I contact Shalini Sharp?: The corporate mailing address for Ms. Sharp and other Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato CA, 94949. Ultragenyx Pharmaceutical can also be reached via phone at (415) 483-8800 and via email at [email protected]. Learn More on Shalini Sharp's contact information.
Has Shalini Sharp been buying or selling shares of Ultragenyx Pharmaceutical?: Shalini Sharp has not been actively trading shares of Ultragenyx Pharmaceutical within the last three months. Most recently, Shalini Sharp sold 14,378 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $88.40, for a transaction totalling $1,271,015.20. Following the completion of the sale, the chief financial officer now directly owns 100,747 shares of the company's stock, valued at $8,906,034.80. Learn More on Shalini Sharp's trading history.
Who are Ultragenyx Pharmaceutical's active insiders?: Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Mardi Dier (CFO), Erik Harris (EVP), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?: During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 137,745 shares worth more than $5,325,628.52. The most recent insider tranaction occured on April, 18th when EVP Eric Crombez sold 142 shares worth more than $6,262.20. Insiders at Ultragenyx Pharmaceutical own 6.8% of the company. Learn More about insider trades at Ultragenyx Pharmaceutical.
Information on this page was last updated on 4/18/2024.

Shalini Sharp Insider Trading History at Ultragenyx Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/17/2020	Sell	14,378	$88.40	$1,271,015.20	100,747
6/3/2020	Sell	10,234	$74.23	$759,669.82	111,442
5/19/2020	Sell	7,128	$73.32	$522,624.96	122,929
3/18/2019	Sell	14,800	$70.00	$1,036,000.00
9/25/2018	Sell	6,700	$90.07	$603,469.00	56,828
6/7/2018	Sell	6,700	$80.07	$536,469.00	60,178
5/30/2018	Sell	13,000	$70.17	$912,210.00	70,174
3/2/2017	Sell	12,000	$90.10	$1,081,200.00	67,887
2/27/2017	Sell	12,000	$80.14	$961,680.00	63,887
11/9/2016	Sell	24,000	$71.20	$1,708,800.00	69,387
10/19/2016	Sell	12,000	$61.40	$736,800.00	57,387
7/20/2015	Sell	3,854	$131.95	$508,535.30
6/18/2015	Sell	4,000	$96.08	$384,320.00
4/20/2015	Sell	4,000	$62.23	$248,920.00
1/20/2015	Sell	4,000	$51.24	$204,960.00
12/18/2014	Sell	4,000	$44.82	$179,280.00
11/20/2014	Sell	4,000	$44.07	$176,280.00
9/18/2014	Sell	4,000	$56.00	$224,000.00
8/18/2014	Sell	4,000	$53.97	$215,880.00
1/30/2014	Buy	4,500	$21.00	$94,500.00

Shalini Sharp Buying and Selling Activity at Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Company Overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $44.24

$43.71

$44.58

50 Day Range

MA: $47.89

$42.31

$53.69

2 Week Range

Now: $44.24

$31.52

$54.98

Volume

450,422 shs

Average Volume

754,900 shs

Market Capitalization

$3.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65